Abortion Drug Gets Approval Even After Commitment to Assess Safety

FDA Approves New Abortion Drug

The U.S. Food and Drug Administration (FDA) has given the green light to a new abortion medication.

This drug, a generic version of mifepristone, was approved by the agency in a letter on Tuesday, although news of its approval didn’t emerge until Thursday.

Many were caught off guard by this decision, especially since it came shortly after Health and Human Services Secretary Robert F. Kennedy Jr. announced on September 19 that the FDA would review the safety of mifepristone.

Senator Josh Hawley, R-Mo., reacted swiftly, expressing his shock on X. “This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,” he tweeted just minutes after the news broke.

Kelsey Pritchard, the director of state public affairs for Susan B. Anthony Pro-Life America, shared her disappointment with The Daily Signal. She seemed to think that the FDA’s decision to announce the approval just as the government was shutting down was “really reckless and disappointing.”

The medication is produced by Evita Solutions LLC, a company aiming to “normalize abortion care” and make it “accessible to all.” Their website highlights the issues surrounding medical abortion care in the U.S., pointing out unnecessary restrictions and social stigma.

Evita Solutions believes that everyone should have access to safe and compassionate abortion care, regardless of various factors like race or income. Their stance seems to suggest that individuals can make the best choices for their bodies.

According to data from the Guttmacher Institute, abortion drugs constituted 63% of all abortions in 2023.

Moreover, research from the Ethics & Public Policy Center indicates that about 11% of women may face severe adverse effects such as hemorrhaging, infections, or sepsis within 45 days following a mifepristone abortion.

Marjorie Dannenfelser, president of SBA Pro-Life America, criticized the approval, stating that these drugs not only take the lives of unborn children but also put women—and even underage girls—in significant danger. She emphasized that this decision undermines pro-life laws across the country.